Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment

Journal of Neurosurgery

Volumn 123, Issue 2, 2015, Pages 395-401

  Ly, David ^a   Bagshaw, Hilary P ^a   Anker, Christopher J ^b   Tward, Jonathan D ^a,c   Grossmann, Kenneth F ^a   Jensen, Randy L ^a   Shrieve, Dennis C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

BRAF; BRAF inhibitor; Brain metastases; Melanoma; Stereotactic radiosurgery

Indexed keywords

B RAF KINASE; DABRAFENIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ADULT; ARTICLE; BLEEDING; BRAIN DYSFUNCTION; BRAIN METASTASIS; BRAIN RADIATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; INTRATUMORAL HEMORRHAGE; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; STEREOTACTIC RADIOSURGERY; ANTAGONISTS AND INHIBITORS; BRAIN; BRAIN NEOPLASMS; GENETICS; MELANOMA; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RADIOSURGERY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; OXIMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RADIOSURGERY; RETROSPECTIVE STUDIES; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944149795     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.9.JNS141425     Document Type: Article

References (42)

1. Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, et al: Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283-e287, 2013
2. Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, et al: Vemurafenib and radiosensitization. JAMA Dermatol 149:855-857, 2013
3. Braunstein I, Gangadhar TC, Elenitsas R, Chu EY: Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption. J Cutan Pathol 41:539-543, 2014
4. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL: Stereotactic radiosurgery for patients with radioresistant brain metastases. Neurosurgery 62 (Suppl 2):790-801, 2008
5. Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, et al: Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23:4127-4136, 2005
6. Castellani E, Covarelli P, Boselli C, Cirocchi R, Rulli A, Barberini F, et al: Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World J Surg Oncol 10:155, 2012
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
9. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, et al: Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611-621, 2014
10. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al: MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106:20411-20416, 2009
11. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
12. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
13. Forschner A, Niessner H, Bauer J, Bender B, Garbe C, Meier F: Successful treatment with vemurafenib in BRAF V600Kpositive cerebral melanoma metastasis. JAMA Dermatol 149:642-644, 2013
14. Ghia AJ, Tward JD, Anker CJ, Boucher KM, Jensen RL, Shrieve DC: Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. J Radiosurg SBRT 3:43-50, 2014
15. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11:909-920, 2012
16. Gumusay O, Coskun U, Akman T, Ekinci AS, Kocar M, Erceleb OB, et al: Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. J Cancer Res Clin Oncol 140:151-157, 2014
17. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
18. Hazard LJ, Wang B, Skidmore TB, Chern SS, Salter BJ, Jensen RL, et al: Conformity of LINAC-based stereotactic radiosurgery using dynamic conformal arcs and micro-multileaf collimator. Int J Radiat Oncol Biol Phys 73:562-570, 2009
19. Jahanshahi P, Nasr N, Unger K, Batouli A, Gagnon GJ: Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. Front Oncol 2:167, 2012
20. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J, et al: Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 65:S17.e1-s17.e11, 2011
21. Jensen RL, Shrieve AF, Samlowski W, Shrieve DC: Outcomes of patients with brain metastases from melanoma and renal cell carcinoma after primary stereotactic radiosurgery. Clin Neurosurg 55:150-159, 2008
22. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, et al: B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-6298, 2004
23. Liebner DA, Walston SA, Cavaliere R, Powers CJ, Sauvageau E, Lehman NL, et al: Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib. Melanoma Res 24:172-176, 2014
24. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al: Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 114:769-779, 2011
25. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012
26. Lwu S, Goetz P, Monsalves E, Aryaee M, Ebinu J, Laperriere N, et al: Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases. Oncol Rep 29:407-412, 2013
27. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF: Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344:655-664, 2013
28. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF: Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342:33-40, 2012
29. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al: Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411-416, 2013
30. Neal MT, Chan MD, Lucas JT Jr, Loganathan A, Dillingham C, Pan E, et al: Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg 82:1250-1255, 2014
31. Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, et al: Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23:879-881, 2013
32. Powell JW, Chung CT, Shah HR, Canute GW, Hodge CJ, Bassano DA, et al: Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg 109 Suppl:122-128, 2008
33. Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, et al: Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31:3844-3845, 2013
34. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM: Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394-399, 2011
35. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11-20, 1998
36. Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R: Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 31:e220-e222, 2013
37. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698-2705, 2002
38. Selek U, Chang EL, Hassenbusch SJ III, Shiu AS, Lang FF, Allen P, et al: Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59:1097-1106, 2004
39. Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, et al: Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Reports 6:131, 2012
40. Trappe R, Budde U, Zimmermann H: Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma. Thromb Haemost 108:798-800, 2012
41. Wang CM, Fleming KF, Hsu S: A case of vemurafenibinduced keratosis pilaris-like eruption. Dermatol Online J 18:7, 2012
42. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al: Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117:1711-1720, 2011